Interventions for dialysis patients with hepatitis C virus (HCV) infection

Attur, Ravindra Prabhu; Nair, Sreekumaran; Pai, Girish K; Reddy, Nageswara P; Suvarna, Deepak

doi:10.1002/14651858.cd007003.pub2

Cited by 8 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon-based regimens had been the backbone of HCV treatment for kidney transplant recipients until 2014, a therapeutic approach limited by the relatively low efficacy in achieving viral eradication, poor tolerability [51, 52], and the obligation to use it only before transplant because of the high risk of inducing immune stimulation and allograft rejection [53–55].…”

Section: Introductionmentioning

confidence: 99%

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

Calogero

Sagnelli

Creta

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection unfavorably affects the survival of both renal patients undergoing hemodialysis and renal transplant recipients. In this subset of patients, the effectiveness and safety of different combinations of interferon-free direct-acting antiviral agents (DAAs) have been analyzed in several small studies. Despite fragmentary, the available data demonstrate that DAA treatment is safe and effective in eradicating HCV infection, with a sustained virologic response (SVR) rates nearly 95% and without an increased risk of allograft rejection. This review article analyzes the results of most published studies on this topic to favor more in-depth knowledge of the readers on the subject. We suggest, however, perseverating in this update as the optimal DAA regimen may not be proposed yet, because of the expected arrival of newer DAAs and of the lack of data from large multicenter randomized controlled trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

Calogero

Sagnelli

Creta

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…UNOS only collects HCV serological data; viral loads for both donors and recipients were not available and we could not distinguish between donors or recipients with active viremia and those who spontaneously cleared the virus or received HCV treatment with a sustained virologic response. However, given the low HCV treatment rates among dialysis patients [ 3 ], it is reasonable to assume that most HCV seropositive recipients have active HCV viremia. HCV genotype information was also not available, making it impossible to identify those with HCV superinfection.…”

Section: Discussionmentioning

confidence: 99%

“…Hepatitis C virus (HCV) infection is more prevalent in ESRD and renal transplant populations compared with the general US population; 4–10% of dialysis patients are HCV-positive (HCV +) [ 1 , 2 ]. Direct-acting antivirals (DAAs) were introduced for the treatment of HCV infection in 2013, but despite this advance in HCV therapy, the majority of patients remain untreated [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes

Cohen

Eddinger

Shelton

et al. 2017

Clinical Kidney Journal

View full text Add to dashboard Cite

BackgroundHepatitis C virus (HCV) infection is common in dialysis patients and renal transplant recipients and has been associated with diminished patient and allograft survival. HCV-positive (HCV+) kidneys have been used in HCV-positive (HCV+) recipients as a means of facilitating transplantation and expanding the organ donor pool; however, the effect of donor HCV serostatus in the modern era is unknown.MethodsUsing national transplant registry data, we created a propensity score–matched cohort of HCV+ recipients who received HCV-positive donor kidneys compared to those transplanted with HCV-negative kidneys.ResultsTransplantation with an HCV+ kidney was associated with an increased risk of death {hazard ratio [HR] 1.43 [95% confidence interval (CI) 1.18–1.76]; P < 0.001} and allograft loss [HR 1.39 (95% CI 1.16–1.67); P < 0.001] compared with their propensity score–matched counterparts. However, HCV+ kidneys were not associated with an increased risk of acute rejection [odds ratio 1.16 (95% CI 0.84–1.61); P = 0.35].ConclusionsWhile use of HCV+ donor kidneys can shorten the wait for renal transplantation and maximize organ utility for all candidates on the waiting list, potential recipients should be counseled about the increased risks associated with HCV+ kidney.

show abstract

“…Poly(ethylene)-glycol (PEG), a water-soluble polymer, is currently used to extend the duration of interferon-alpha in humans as treatment for hepatitis C and can aid in the stimulation of neutrophil production in neutropenia. 9 , 10 The hydrogels manufactured from this polymer can be functionalized to provide cell attachment and degradation sites and may also be adapted for use in drug delivery systems and as substrates for cell transplantation. 11 – 13 The chemical versatility of PEG allows for the incorporation and modification of components that create a synthetic ECM closely mimicking an environment that, at the molecular level, can specifically interact with a given cell type in a directed manner.…”

Section: Introductionmentioning

confidence: 99%

Cell-mediated remodeling of biomimetic encapsulating hydrogels triggered by adipogenic differentiation of adipose stem cells

et al. 2016

View full text Add to dashboard Cite

One of the most common regenerative therapies is autologous fat grafting, which frequently suffers from unexpected volume loss. One approach is to deliver adipose stem cells encapsulated in the engineered hydrogels supportive of cell survival, differentiation, and integration after transplant. We describe an encapsulating, biomimetic poly(ethylene)-glycol hydrogel, with embedded peptides for attachment and biodegradation. Poly(ethylene)-glycol hydrogels containing an Arg–Gly–Asp attachment sequence and a matrix metalloprotease 3/10 cleavage site supported adipose stem cell survival and showed remodeling initiated by adipogenic differentiation. Arg–Gly–Asp–matrix metalloprotease 3/10 cleavage site hydrogels showed an increased number and area of lacunae or holes after adipose stem cell differentiation. Image analysis of adipose stem cells in Arg–Gly–Asp–matrix metalloprotease 3/10 cleavage site hydrogels showed larger Voronoi domains, while cell density remained unchanged. The differentiated adipocytes residing within these newly remodeled spaces express proteins and messenger RNAs indicative of adipocytic differentiation. These engineered scaffolds may provide niches for stem cell differentiation and could prove useful in soft tissue regeneration.

show abstract

Interventions for dialysis patients with hepatitis C virus (HCV) infection

Cited by 8 publications

References 53 publications

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes

Cell-mediated remodeling of biomimetic encapsulating hydrogels triggered by adipogenic differentiation of adipose stem cells

Contact Info

Product

Resources

About